Cantor Fitzgerald Reiterates Overweight Rating for uniQure (NASDAQ:QURE)

by · The Cerbat Gem

uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued on Wednesday, Benzinga reports. They presently have a $28.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 339.56% from the company’s previous close.

QURE has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, August 20th. StockNews.com raised uniQure to a “sell” rating in a research report on Thursday, October 17th. The Goldman Sachs Group lifted their target price on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Finally, Raymond James reaffirmed an “outperform” rating and set a $20.00 target price on shares of uniQure in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, uniQure has an average rating of “Hold” and a consensus target price of $19.50.

Get Our Latest Report on uniQure

uniQure Trading Up 5.1 %

Shares of uniQure stock traded up $0.31 on Wednesday, reaching $6.37. The company had a trading volume of 22,540 shares, compared to its average volume of 1,405,800. The firm’s 50-day moving average price is $5.68 and its two-hundred day moving average price is $5.78. uniQure has a 1 year low of $3.73 and a 1 year high of $11.35. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.36 and a quick ratio of 7.36. The firm has a market cap of $310.21 million, a price-to-earnings ratio of -1.07 and a beta of 0.90.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in the company. abrdn plc grew its stake in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Vanguard Group Inc. grew its stake in uniQure by 11.4% during the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares during the last quarter. Privium Fund Management B.V. grew its stake in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares during the last quarter. BNP Paribas Financial Markets grew its stake in uniQure by 4.3% during the 1st quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after purchasing an additional 30,054 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in uniQure by 133.1% during the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Further Reading